A by-product from Utah-based Intermountain Well being has raised $10 million to deliver longitudinal organic and scientific information to biopharmaceutical corporations. 

End result Bio says it maintains unique rights to a bodily library and cloud-based information lake overlaying over 40 years of de-identified affected person digital well being information and biospecimen information. This intensive information lake can allow biopharmaceutical corporations to achieve insights essential to facilitating diagnostic and therapeutic improvement. 

The corporate notes that it will probably take over a decade and billions of {dollars} to acquire regulatory approval for therapies or diagnostic instruments. The issue begins with having access to longitudinal organic and scientific affected person information, which might take life sciences and biotech corporations months to gather and course of.   

With a repeatedly rising library of over 5 million de-identified affected person samples and scientific information spanning many years, End result Bio can provide speedy entry to retrospective affected person information and quicker entry to 1000’s of potential sufferers for research.

The $10 million funding is from Merck World Well being Innovation Fund and Amgen Ventures. 

“With assist from our traders, End result Bio is elevating the bar for healthcare innovation,” mentioned Lincoln Nadauld, M.D., Ph.D., president and CEO of End result Bio, in an announcement. He was beforehand vp, chief of precision well being & teachers at Intermountain. 

“On high of our present longitudinal affected person information, we’re including over 300,000 biospecimens to our information lake every year,” Nadauld added. “Due to this, we’ve got the power to shortly determine distinctive affected person cohorts from our huge information lake that may pace up essential analysis, resulting in novel discoveries..”

Along with rushing up affected person recruitment, the brand new firm mentioned the platform gives fast question capabilities throughout genomic, organic, scientific, and claims information, which has already supported analysis on every thing from population-wide genetic research to drug discovery.

“End result’s Intelligence Platform gives collaborators with entry to uniquely wealthy de-identified scientific datasets,” mentioned David M. Rubin, Ph.D., managing director at Merck World Well being Innovation Fund (GHIF), in an announcement. “GHIF seems ahead to working with the proficient and skilled End result administration staff to harness the facility of precision medication to enhance outcomes for sufferers.”